Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00649-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Masayasu Hidaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Drug Industry, Drug Approval. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
We examined the development strategies of new molecular entities approved during a 10-year period (fiscal years of 2012-2021) in Japan to determine the differences in drug lag between Japan and foreign companies. The results demonstrated a clear difference in development strategies. For example, products were usually developed through a "only-Japan" strategy by Japan companies (51.1% of products), compared to a "MRCT (multi-regional clinical trials)" strategy by foreign companies (54.9% of products). Regarding types of licenses, for Japan companies, the percentage of original products was higher in the category of less drug lag, such as "no approval in the US and EU" (59.1%), whereas the percentage of "license-in" products was markedly higher in the "drug lag ≥ 5 years" category (52.5%). Such differences were not observed for products developed by foreign companies. Of 64 license-in products developed by Japan companies with a drug lag > 5 years, 51 (79.7%) had already been approved in the US or EU at initiation of clinical development in Japan. The origin of approximately half (34) of the products was from the emerging companies (non-member foreign companies of the Japan Pharmaceutical Manufacture Association). These results suggest that more global cooperation of Japan companies, particularly with emerging foreign companies, is necessary in terms of the earlier timing of license-in and development strategies of products to promote drug development without drug lag or drug loss in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Global Regulatory Sciences Japan, Bristol-Myers Squibb K.K., Tokyo, Japan.
- Division of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
- Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan. uyama-yoshiaki@pmda.go.jp.
- Regulatory Science Center, Pharmaceuticals and Medical Devices Agency, Shin‑Kasumigaseki Building, 3‑3‑2, Kasumigaseki, Chiyoda‑ku, Tokyo, 100‑0013, Japan. uyama-yoshiaki@pmda.go.jp.
- Graduate School of Medicine, Nagoya University, Nagoya, Japan. uyama-yoshiaki@pmda.go.jp.
ORCID-Profile: Yoshiaki Uyama
Zitieren
APA
Hidaka, M., Hanaoka, H., & Uyama, Y. (2024). Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00649-y
Vancouver
Hidaka M, Hanaoka H, Uyama Y. Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00649-y
BibTeX
@article{Hidaka2024,
author = {Hidaka, Masayasu and Hanaoka, Hideki and Uyama, Yoshiaki},
title = {Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00649-y}
}
EUVIMED